Given this uncertain impact of WT1 mutation on transplant outcome, we performed a contemporary registry-based real-life study using data of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT), comparing the outcomes of HSCT in patients with mWT1 AML in first complete remission (CR1) with that of patients with wild-type WT1 (wtWT1). Here, WT1 is linked to acute myeloid leukemia.